Blog
RSS FeedPosted by Michael Wonder on 17 Jan 2018
Pfizer asked to submit CDF proposal for Xalkori
17 January 2018 - Pfizer’s Xalkori has been turned away by NICE to treat ROS1-positive advanced non-small cell lung cancer. ...
Posted by Michael Wonder on 14 Jan 2018
A managed access approach to appraising new cancer drugs in England
12 January 2018 - The changing regulatory landscape brings new challenges to health technology assessment. Marketing authorisations are being granted as ...
Posted by Michael Wonder on 08 Jan 2018
NICE to look again at Pfizer’s Besponsa after appeal
3 January 2018 - The blood cancer medicine was originally turned down on cost-effectiveness grounds. ...
Posted by Michael Wonder on 20 Dec 2017
Takeda’s Ninlaro approved for NHS use via Cancer Drugs Fund
20 December 2017 - Patients in England and Wales will now be able to access Takeda’s myeloma treatment Ninlaro on ...
Posted by Michael Wonder on 14 Dec 2017
NICE changes its mind on Imbruvica for mantle cell lymphoma
14 December 2017 - In a reversal of a previous guidance, the UK’s NICE has issued draft guidance recommending ibrutinib ...
Posted by Michael Wonder on 11 Dec 2017
NICE U-turn backs combo for kidney cancer
11 December 2017 - In a turnaround from its earlier position, the NICE is now endorsing NHS funding for Eisai’s ...
Posted by Michael Wonder on 09 Dec 2017
NICE nods for AbbVie in hepatitis C and Novartis in lung cancer
8 December 2017 - NICE has published new draft guidance for Novartis' Zykadia and AbbVie's Maviret. ...
Posted by Michael Wonder on 08 Dec 2017
New deal will give people with kidney cancer another treatment option
8 December 2017 - People with advanced kidney cancer are set to benefit from a new treatment, after NICE has said ...
Posted by Michael Wonder on 07 Dec 2017
Roche’s Tecentriq available via CDF
7 December 2017 - Roche’s Tecentriq will be available on the NHS in England via the Cancer Drugs Fund for ...
Posted by Michael Wonder on 27 Nov 2017
NICE no for Halaven in new indication
27 November 2017 - A lack of clinical evidence proving its effectiveness has led NICE to publish draft guidance refusing ...
Posted by Michael Wonder on 27 Nov 2017
Merck invited to submit a CDF proposal for Merkel cell cancer drug
27 November 2017 - NICE has asked Merck to submit a Cancer Drugs Fund proposal for an immunotherapy called avelumab. ...
Posted by Michael Wonder on 23 Nov 2017
Roche’s Erivedge no longer funded by the NHS
23 November 2017 - Roche’s Erivedge will indeed no longer be funded on the National Health Service as a treatment ...
Posted by Michael Wonder on 20 Nov 2017
Bayer’s Stivarga wins NICE approval for GIST
20 November 2017 - Bayer’s Stivarga has been recommended by the National Institute for Health and Care Excellence as a ...
Posted by Michael Wonder on 16 Nov 2017
Breast cancer patients to have routine access to two life extending drugs after new deal, say NICE in draft guidance
16 November 2017 - NICE has recommended palbociclib and ribociclib for routine funding after the companies lowered the prices and gave ...
Posted by Michael Wonder on 12 Nov 2017
NHS England, Roche come to agreement on Perjeta
10 November 2017 - NHS England and Roche have agreed a confidential commercial agreement on the price of Perjeta for ...